Cargrilintide is an investigational peptide analog of amylin, primarily studied for weight management and glucose regulation. It mimics the appetite-suppressing effects of amylin, a hormone co-secreted with insulin.

Science:

• Modulates appetite and satiety centers in the brain.

• Slows gastric emptying, contributing to reduced calorie intake.

• Investigated in animal models and early human studies for obesity and metabolic disorders.

Potential Benefits (Research-Based):

• May reduce body weight and fat mass.

• Supports appetite suppression in obesity studies.

• Could aid glucose regulation in combination with other metabolic interventions.